NCT07467382 GOAT (Gait Observation of Achilles Tendon)
| NCT ID | NCT07467382 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nantes University Hospital |
| Condition | Spastic Paresis |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-06-01 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2026-06-01 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the mechanical properties of the Achilles tendon (stiffness, length, volume) and the force production capacities of the gastrocnemius medialis muscle in patients with spastic paresis (post-stroke or incomplete spinal cord injury) compared to healthy subjects, during gait.
Eligibility Criteria
Inclusion Criteria: Study population: • Cognitive abilities compatible with the experiment: no language or judgement disorders preventing understanding of the research or expression of consent. An aphasia severity score greater than or equal to 3 on the Boston Diagnostic Aphasia Examination (BDAE) scale will be required for inclusion. Post-stroke population: * Adult male or female * Patient who has had a stroke \> 7 days ago * Patient hospitalised (in conventional hospitalisation or day hospital) in the neurological physical and medical rehabilitation department of Nantes University Hospital * Patients with voluntary motor function rated between 2 and 4 on the MRC (Medical Research Council) scale at the GM level * Patients classified as 3 to 8 on the New Functional Ambulation Classification * Indication to perform a quantified gait analysis as part of clinical management Post-spinal cord injury population: * Adult men or women * Patients with incomplete spinal cord injury graded ASIA AIS C or D from C2 to L5 * Patients hospitalised (in conventional hospitalisation or day hospital) in the neurological physical and occupational therapy department of Nantes University Hospital * Patients with voluntary motor function rated between 2 and 4 on the MRC (Medical Research Council) scale at GM level * Patients rated 13-20 on the WISCI-II scale * Indication for a quantified gait analysis as part of clinical care Healthy population: • Adult men or women with no nervous system disorders. Exclusion Criteria: Post-stroke and post-spinal cord injury population: * Minors; * History of calf surgery, surgery to reduce triceps surae spasticity, or intramuscular injection (e.g. botulinum toxin) in the plantar flexors \< 6 months; * Patients with a progressive condition that contraindicates exertion (syrinx, cardiovascular instability); * Peripheral pathology of the lower limb in question. Healthy population: * History of calf surgery; * History of muscle injury, fracture or sprain of the lower limb \< 3 months; * History of neurological condition.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07467382 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Spastic Paresis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07467382 currently recruiting?
Yes, NCT07467382 is actively recruiting participants. Contact the research team at thomas.lecharte@chu-nantes.fr for enrollment information.
Where is the NCT07467382 trial being conducted?
This trial is being conducted at Nantes, France.
Who is sponsoring the NCT07467382 clinical trial?
NCT07467382 is sponsored by Nantes University Hospital. The trial plans to enroll 60 participants.